Enanta Pharmaceuticals (CH:9EP)
NASDAQ:9EP
9EP Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9EP Stock 12 Month Forecast
Average Price Target
$15.79
| Highest Price Target$15.79 | Average Price Target$15.79 | Lowest Price Target$15.79 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
CHF15.79
Buy
―
Reiterated
05/12/26
J.P. Morgan
CHF15
Buy
―
Reiterated
03/03/26
Jefferies
CHF11.05→CHF15.79
Buy
―
Upgraded
10/01/25
Leerink Partners
CHF5.53→CHF7.1
Hold
―
Reiterated
10/01/25
Evercore ISI
CHF9.47
Buy
―
Reiterated
09/30/25
Citizens JMP
CHF18.94→CHF19.73
Buy
―
Reiterated
08/12/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
CHF15.79
Buy
―
Reiterated
05/12/26
J.P. Morgan
CHF15
Buy
―
Reiterated
03/03/26
Jefferies
CHF11.05→CHF15.79
Buy
―
Upgraded
10/01/25
Leerink Partners
CHF5.53→CHF7.1
Hold
―
Reiterated
10/01/25
Evercore ISI
CHF9.47
Buy
―
Reiterated
09/30/25
Citizens JMP
CHF18.94→CHF19.73
Buy
―
Reiterated
08/12/25
Best Analysts Covering Enanta Pharmaceuticals
3 Months
Success Rate
13/37 ratings generated profit
Average Return
-4.74%
Copying Roy Buchanan's trades and holding each position for 3 Months would result in 35.14% of your transactions generating a profit, with an average return of -4.74% per trade.
1 Year
Success Rate
11/37 ratings generated profit
Average Return
-13.99%
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 29.73% of your transactions generating a profit, with an average return of -13.99% per trade.
2 Years
Success Rate
12/37 ratings generated profit
Average Return
-29.42%
Copying Roy Buchanan's trades and holding each position for 2 Years would result in 32.43% of your transactions generating a profit, with an average return of -29.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9EP Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
2
2
1
Buy
3
4
4
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
6
6
4
2
Each month's total comprises the sum of three months' worth of ratings.
9EP Financial Forecast
9EP Stock Forecast FAQ
What is CH:9EP’s average 12-month price target, according to analysts?
Based on analyst ratings, Enanta Pharmaceuticals’s 12-month average price target is 15.79.
What is CH:9EP’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:9EP, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Enanta Pharmaceuticals a Buy, Sell or Hold?
Enanta Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Enanta Pharmaceuticals’s share price target?
The average share price target for Enanta Pharmaceuticals is 15.79. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $15.79 ,and the lowest forecast is $15.79. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is $15.79 ,and the lowest forecast is $15.79. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Enanta Pharmaceuticals?
Enanta Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Enanta Pharmaceuticals?
To buy shares of CH:9EP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.